Showing Latest Articles
Comparative Long Term Effects of Nebivolol and Carvedilol in Hypertensive Heart Failure Patients
Journal of Cardiac Failure, 08/31/2011
Clinical Article
Marazzi G et al. – In the long term, nebivolol and carvedilol appear to be similarly effective in the treatment of hypertensive patients with chronic heart failure (CHF).
Methods- A total of 160 hypertensive CHF patients, with LVEF <40% and in New York Heart Association (NYHA) functional class I, II, or III, were randomly assigned to receive nebivolol or carvedilol for 24 months.
- At baseline and at the end of treatment, all patients underwent clinical evaluation, echocardiography, and 6–minute walking test.
- The target doses were 10 mg/d for nebivolol and 50 mg/d for carvedilol.
- Compared with baseline values, LVEF increased by a similar extent in the carvedilol (C) and nebivolol (N) groups (C from 36.1% (SD 1.5%) to 40.9% (SD 1.9%), P < .001; N from 34.1% (SD 1.8%) to 38.5% (SF 2.2%), P < .001).
- Heart rate and NYHA functional class decreased significantly in both groups, and the 6–minute walking distance increased (C from 420 m (SD 104 m) to 490 m (SD 115 m), P < .001; N from 421 m (SD 118 m) to 487 m (SD 138 m), P < .001).
- During 24 months, 21 carvedilol recipients (26%) and 18 nebivolol recipients (22%) had cardiac events, including 3 and 4 deaths, respectively.
